Stock ATRA ATARA BIOTHERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Atara Biotherapeutics, Inc.

Equities

ATRA

US0465131078

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-07 pm EDT 		5-day change 1st Jan Change
0.5288 USD -7.08% Intraday chart for Atara Biotherapeutics, Inc. -5.72% +3.12%
May. 20 Sector Update: Health Care Stocks Ease Monday Afternoon MT
May. 20 Atara Biotherapeutics Files Biologics License Application for Tabelecleucel with FDA; Shares Rise MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BU
Atara Biotherapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
BU
Atara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual Meeting
BU
Atara Biotherapeutics Submits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA
BU
Atara Biotherapeutics: Q1 Earnings Snapshot
AQ
Atara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress
BU
ATARA BIOTHERAPEUTICS, INC. REPORTS INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(4)
AQ
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BU
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BU
Atara Biotherapeutics: Q4 Earnings Snapshot
AQ
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress
BU
Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy
BU
Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care Conference
BU
Atara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis
BU
Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel® Data in The Lancet Oncology
BU
Latest Buzz on The Street: Noteworthy Developments at DYAI, ELEV, ATRA, ESPR, KAVL
AQ
Atara Biotherapeutics Announces $15 Million Registered Direct Offering
BU
Atara Biotherapeutics to Present Recent Progress and Key Upcoming Milestones at the 42nd Annual J.P. Morgan Healthcare Conference
BU
Atara Biotherapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
BU
Atara Biotherapeutics Announces Closing of Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ATRA Stock
  4. News Atara Biotherapeutics, Inc.
  5. Press Releases